A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
NCT07812090
Summary
The purpose of this study is to learn about the effects of BGE-102 on change in vision in participants with center-involved diabetic macular edema (CI-DME). BGE-102 decreases inflammation which may improve vision or slow the progression of vison loss in those with CI-DME. Participants will be randomized to one of 3 arms and receive either BGE-102 in combination with an anti-vascular endothelial growth factor (anti-VEGF) drug, BGE-102 in combination with sham injection, or BGE-102 placebo in combination with an anti-VEGF drug. This study will also evaluate safety and tolerability of BGE-102.
Eligibility
Inclusion Criteria: * Adults 18-75 years of age * Type 1 or Type 2 Diabetes diagnosis * Diabetic Macular Edema (DME) affecting the center of vision * Study Eye may be treatment naïve (never received treatment) or previously treated and if previously treated, meets washout requirements * Acceptable Vision as measured by an eye chart * Visual Acuity and retinal thickness as measured by an eye scan, results meeting eligibility criteria * Willing to use birth control, if applicable Exclusion Criteria: * Significant ocular disease, condition, or prior ocular treatment and/ or procedure that could affect vision, study assessments, or participant safety, including failure to meet required treatment washout periods * Macular edema in the study eye due to causes other than DME, such as retinal vein occlusion, uveitis, neovascular age-related macular degeneration * Significant macular ischemia in the study eye that would limit visual improvement as assessed by the Investigator and confirmed by the Reading Center * Uncontrolled diabetes * Uncontrolled blood pressure * Medically unstable cardiac conditions and/or medically important ECG abnormalities. * Relevant medical or psychiatric condition(s) that put the participant at risk or will make implementation of the protocol or interpretation of the study difficult. * Women who are pregnant or nursing
Conditions2
Interventions3
Locations1 site
Find trials near these locations
Related trials
- Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC — Shanghai Zhongshan Hospital
- BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases — Shandong Cancer Hospital and Institute
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07812090